Press Releases Archives

QuartzBio Secures Investment - Scott Marshall Announcement May 2026

New capital fuels product enhancements as leading biopharma adopt QuartzBio to eliminate operational inefficiencies and protect trial outcomes

Baltimore, MD — [May 13, 2026] — QuartzBio, a life science technology company delivering portfolio‑scale sample and biomarker intelligence for clinical‑stage biopharma, today announced a strategic growth investment and controlling interest from Eir Partners, a private equity firm focused on health tech and tech-enabled services. The move marks a significant milestone as QuartzBio expands its role as trusted infrastructure for biopharma organizations seeking greater operational control, data integrity, and efficiency across complex clinical trial portfolios.

Addressing a Growing Operational Bottleneck in Clinical Development

As clinical trial portfolios scale, sponsors are forced to manage biospecimens and biomarker data across disconnected vendors, systems, and spreadsheets. This fragmentation introduces operational blind spots—driving missing or unusable samples, manual consent and collection tracking, late discovery of data gaps, costly downstream rework, and trial delays.

QuartzBio was built to eliminate this friction. Its vendor‑agnostic, AI‑enabled platform unifies sample collection, chain of custody, consent status, metadata integrity, and biomarker results into a single ecosystem—delivering real‑time visibility and control across entire clinical portfolios.

Proven Impact Across Clinical Operations

QuartzBio is trusted by a growing customer base that includes multiple Top 10 pharmaceutical companies, delivering operational clarity across complex clinical programs. The platform helps teams identify and resolve issues early—before they become protocol deviations, data loss, or trial delays—while integrating seamlessly into existing workflows.

Customers report near‑complete visibility into sample collection, reducing monitoring effort by up to 98% and significantly cutting manual work through automated oversight and exception management—allowing teams to support significantly more studies without adding headcount. These efficiencies drive $250K–$350K in average savings per Phase II/III study, while protecting timelines and ensuring biomarker‑ready data at readout.

By embedding domain‑specific AI directly into clinical and translational workflows, QuartzBio enables R&D teams to move faster and with greater confidence—without increasing operational risk or administrative burden.

Focused Investment in Product and Scale

The investment from Eir Partners enables QuartzBio to accelerate enhancements across its platform and operating model, including:

Expanded portfolio‑scale interoperability across CROs, labs, and clinical systems
Deeper AI‑driven automation for workflow management, risk detection, and data completeness
Enhanced analytics and benchmarking for multi-trial decision‑making
Increased enterprise scalability, security, and global compliance
Expanded customer support and implementation capacity to match growing adoption

“Modern clinical development generates unprecedented volumes of data, yet trial risk persists because that data is fragmented, delayed, or unreliable,” said Scott Marshall, Ph.D., CEO of QuartzBio. “This investment allows us to double down on delivering a scalable software platform that removes manual oversight, protects scientific integrity, and materially reduces trial cost and duration.”

Investor Perspective

“AI is fundamentally transforming clinical development, and sample and biomarker intelligence represents one of its highest-impact applications,” said Brett Carlson, Founder and Chief Executive Officer of Eir Partners. “QuartzBio has demonstrated both strong product‑market fit and tangible economic impact for sponsors managing complex portfolios. By embedding domain-specific AI directly into clinical and translational workflows, the company is well positioned to shape how next-generation trials are conducted.”

Terms of the transaction with Eir Partners were not disclosed. Bourne Partners served as an exclusive financial advisor to QuartzBio.

About QuartzBio

QuartzBio is a life science technology company delivering connected sample and biomarker intelligence for clinical-stage biopharma. Designed for modern, multi-trial portfolios, its vendor‑agnostic platform unifies sample operations and biomarker data into a single platform—powered by domain‑specific AI agents—to reduce operational risk, accelerate timelines, and enable scientifically defensible outcomes. Stay in touch by following us on LinkedIn!

About Eir Partners

Eir Partners Capital is a Miami-based private equity company focused on healthcare technology and tech-enabled services. Founded in 2015, Eir has partnered with entrepreneurs and management teams to create scaled, strategically differentiated platforms across payer, provider, employer, and pharma technology sectors. The Firm’s hands-on approach combines operational insight with deep industry relationships to drive long-term value. Targeted stages of investment include growth equity through control buyouts and equity check sizes range from $40 – $150 million or larger with co-investments. For more information, please visit their website at www.eirpartners.com or LinkedIn page.

QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning, and R&D productivity.

Frederick, MD – January 24, 2023 – Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.

SolveBio’s intelligent technologies and enterprise data management platform has integrated into QuartzBio’s suite of SaaS solutions, providing a single, scalable solution supporting clinical sample inventory management and biomarker data management for the biotech and pharmaceutical sectors.

The combined offerings under QuartzBio provide scientific and operations teams in drug development with an agile, user-friendly data management platform that enables enterprise-level visibility across the lifecycle of their sample and biomarker data. Leveraging this expanded enterprise suite of solutions, scientists in translational research and clinical operations can more easily collaborate across functions, analyze and report on key datasets, and generate insights.

“We are excited to have SolveBio joining forces with QuartzBio,” says Scott Marshall, Ph.D., General Manager of QuartzBio. “As our industry continues to innovate, it is imperative that we continue to advance our portfolio of enterprise solutions to enable scale and connectivity in support of our ultimate goal – delivering therapies to patients. Integrating SolveBio’s technology with QuartzBio’s existing portfolio helps us accomplish that.”

QuartzBio’s fully connected, end-to-end SaaS solutions are engineered to enable seamless monitoring and tracking of clinical sample status, informed consent form (ICF) tracking/codification, and management of biomarker data across the enterprise, resulting in a unified solution for the management and delivery of both samples and their related biomarker data. The platform is used to generate scientific and operational insights, while studies are in progress, after studies are complete, and across multiple clinical programs.

Combining the QuartzBio and SolveBio teams’ expertise and scale, QuartzBio can now better support clients’ strategic goals and day-to-day productivity by helping clinical and translational teams:

Save time with technology that maps data as-is, from any source, using the format provided by the lab, vendor, or other source systems with no changes required—increasing flexibility and speeding deployment.
Gain visibility into sample status with virtual Sample Inventory Management, a single source of truth linking samples and derivatives with clinical data, informed consent, shipping status, and more – across multiple sites, labs, and repositories.
Increase efficiency and reporting accuracy with enterprise-wide Biomarker Data Management, as all sample-related data will be centralized and harmonized in a unified data platform, thus eliminating the need to search for data in multiple storage locations.
Consolidate visibility to stored samples from all studies (active and inactive) with virtual Biorepository, across geographies, biorepositories, and central labs (long-term storage) to facilitate planning for future data generation.
Collaborate and connect by leveraging biomarker-specific visualizations (e.g., genomic and flow data modules), shareable dashboards, internal and external notifications, and application programming interfaces (APIs)/connectors that allow the QuartzBio solutions to empower decision making in the context of a complex data ecosystem.

“We’re very excited to join Precision for Medicine and become a part of QuartzBio,” says Mark Kaganovich, SolveBio’s Co-Founder and CEO. “It’s a big opportunity to continue improving our offering to our customers.” “QuartzBio’s acquisition of SolveBio is a major step forward in our goal to solve biomarker data management for the pharmaceutical and biotech industry,” says David Caplan, SolveBio’s Co-Founder and CTO. “By joining QuartzBio’s amazing team, we will be able to provide the comprehensive solution our clients need to get precision treatments out to patients faster. We are honored to be a part of this journey.”

About QuartzBio

QuartzBio helps overcome the data chaos inherent in modern drug development. We serve clinical operations and translational research teams in oncology, autoimmune, CNS and other biomarker-rich therapeutic areas, whose progress hinges on navigating and connecting a complex data ecosystem. Our suite of fully connected, end-to-end SaaS solutions is engineered specifically to address the challenges of both sample data and biomarker data management – providing a single, scalable data platform solution to the biotech and pharma sectors. For more information, visit Quartzbio.com.

About SolveBio

SolveBio is an industry leader in advanced precision medicine data analytics. Its technology platform enables biopharma customers to lower trial risk, create more effective therapeutics, and compress the time scale of clinical development. The core of SolveBio’s platform is technology to connect genomic data that comes from a rapidly compounding complex landscape of vendors, studies, and patients.

New York, NY & Bethesda, MD — November 20, 2020 — Precision Medicine Group (PMG) and Blackstone (NYSE: BX) today announced that PMG, a leading next-generation provider of drug development and commercialization services, has completed a major investment and recapitalization led by funds managed by Blackstone (“Blackstone”). The investment includes significant participation from Precision’s co-founders, Ethan Leder and Mark Clein, as well as current shareholders Berkshire Partners, TPG Growth, Oak HC/FT, and Vida Ventures.